CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2020; 80(11): 1115-1122
DOI: 10.1055/a-1270-7481
GebFra Science
Review/Übersicht

Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer

Article in several languages: English | deutsch
Hans Tesch
1  Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
,
Volkmar Müller
2  Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Achim Wöckel
3  Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Johannes Ettl
4  Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
,
Erik Belleville
5  ClinSol GmbH & Co. KG, Würzburg, Germany
,
Florian Schütz
6  Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
,
Andreas Hartkopf
7  Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Marc Thill
8  Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Jens Huober
9  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Peter A. Fasching
10  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans-Christian Kolberg
11  Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Carla E. Schulmeyer
10  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Manfred Welslau
12  Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Friedrich Overkamp
13  OncoConsult Overkamp, Berlin, Germany
,
Tanja N. Fehm
14  Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Michael P. Lux
15  Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
,
Andreas Schneeweiss
16  National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Diana Lüftner
17  Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
,
Wolfgang Janni
9  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
› Author Affiliations

Abstract

Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.



Publication History

Received: 30 July 2020

Accepted after revision: 23 September 2020

Publication Date:
06 November 2020 (online)

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany